IMPACT OF BONE MARROW FIBROSIS IN MYELOMA PATIENTS UNDERGONE AUTOLOGOUS STEM CELL TRANSPLANTATION

Objective: Autologous hematopoetic stem cell transplantation (aHSCT) after high dose chemotherapy is a standard treatment for multiple myeloma (MM) patients. The successful aHSCT depends on collection of sufficient numbers of hematopoietic progenitor stem cells and sustained engraftment following in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Senem Maral, Murat Albayrak, Berna Afacan Öztürk, Ünsal Han, Merih Reis Aras, Gülten Korkmaz, Simten Dagdas, Aynur Albayrak, Gülsüm Özet
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/8fa8c444a7b34afba6e5cafc7670057e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8fa8c444a7b34afba6e5cafc7670057e
record_format	dspace
spelling	oai:doaj.org-article:8fa8c444a7b34afba6e5cafc7670057e2021-11-10T04:32:36ZIMPACT OF BONE MARROW FIBROSIS IN MYELOMA PATIENTS UNDERGONE AUTOLOGOUS STEM CELL TRANSPLANTATION2531-137910.1016/j.htct.2021.10.973https://doaj.org/article/8fa8c444a7b34afba6e5cafc7670057e2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011202https://doaj.org/toc/2531-1379Objective: Autologous hematopoetic stem cell transplantation (aHSCT) after high dose chemotherapy is a standard treatment for multiple myeloma (MM) patients. The successful aHSCT depends on collection of sufficient numbers of hematopoietic progenitor stem cells and sustained engraftment following infusion. The aim of the present study is to determine the the impact of bone marrow fibrosis (BMF) on the clinical outcomes of MM patients who underwent aHSCT. Methodology: Retrospectively, bone marrow trephine biopsy analyzed in 73 MM patients who were treated with hematopoietic stem cell transplantation (aHSCT) following bortezomib based induction regimen. The BM biopsy samples of all patients were re-evaluated by a single pathologists The patients divided into 4 groups according to fibrosis degree and the correlations in initial characteristic features, therapeutic response, survival, mobilization and engraftment outcomes were reviewed between the groups. Results: Comparative analyses revealed that the median apheresis number was found statistically different according to groups (p=0.04). No significance was detected between the fibrozis grade and the number of peripheral blood CD34+ cell collection results and recovery time of neutrophils and platelets. Overall survival and progression free survival were found similar in groups, however relapse of disease was statistically different in patients with fibrosis (p=0.01). Conclusion: After induction treatment, a regression was observed in fibrosis grade of patients who had fibrosis at the time of diagnosis. Therefore we suggest to evaluate fibrosis status in all MM patients during each histopathological examination. Difficulties may be experienced during stem cell collection in transplant eligible MM patients with fibrosis at diagnosis. Therefore, we recommend that clinicians should be more careful in these patients during the induction treatment and stem cell mobilization.Senem MaralMurat AlbayrakBerna Afacan ÖztürkÜnsal HanMerih Reis ArasGülten KorkmazSimten DagdasAynur AlbayrakGülsüm ÖzetElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S17- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Senem Maral Murat Albayrak Berna Afacan Öztürk Ünsal Han Merih Reis Aras Gülten Korkmaz Simten Dagdas Aynur Albayrak Gülsüm Özet IMPACT OF BONE MARROW FIBROSIS IN MYELOMA PATIENTS UNDERGONE AUTOLOGOUS STEM CELL TRANSPLANTATION
description	Objective: Autologous hematopoetic stem cell transplantation (aHSCT) after high dose chemotherapy is a standard treatment for multiple myeloma (MM) patients. The successful aHSCT depends on collection of sufficient numbers of hematopoietic progenitor stem cells and sustained engraftment following infusion. The aim of the present study is to determine the the impact of bone marrow fibrosis (BMF) on the clinical outcomes of MM patients who underwent aHSCT. Methodology: Retrospectively, bone marrow trephine biopsy analyzed in 73 MM patients who were treated with hematopoietic stem cell transplantation (aHSCT) following bortezomib based induction regimen. The BM biopsy samples of all patients were re-evaluated by a single pathologists The patients divided into 4 groups according to fibrosis degree and the correlations in initial characteristic features, therapeutic response, survival, mobilization and engraftment outcomes were reviewed between the groups. Results: Comparative analyses revealed that the median apheresis number was found statistically different according to groups (p=0.04). No significance was detected between the fibrozis grade and the number of peripheral blood CD34+ cell collection results and recovery time of neutrophils and platelets. Overall survival and progression free survival were found similar in groups, however relapse of disease was statistically different in patients with fibrosis (p=0.01). Conclusion: After induction treatment, a regression was observed in fibrosis grade of patients who had fibrosis at the time of diagnosis. Therefore we suggest to evaluate fibrosis status in all MM patients during each histopathological examination. Difficulties may be experienced during stem cell collection in transplant eligible MM patients with fibrosis at diagnosis. Therefore, we recommend that clinicians should be more careful in these patients during the induction treatment and stem cell mobilization.
format	article
author	Senem Maral Murat Albayrak Berna Afacan Öztürk Ünsal Han Merih Reis Aras Gülten Korkmaz Simten Dagdas Aynur Albayrak Gülsüm Özet
author_facet	Senem Maral Murat Albayrak Berna Afacan Öztürk Ünsal Han Merih Reis Aras Gülten Korkmaz Simten Dagdas Aynur Albayrak Gülsüm Özet
author_sort	Senem Maral
title	IMPACT OF BONE MARROW FIBROSIS IN MYELOMA PATIENTS UNDERGONE AUTOLOGOUS STEM CELL TRANSPLANTATION
title_short	IMPACT OF BONE MARROW FIBROSIS IN MYELOMA PATIENTS UNDERGONE AUTOLOGOUS STEM CELL TRANSPLANTATION
title_full	IMPACT OF BONE MARROW FIBROSIS IN MYELOMA PATIENTS UNDERGONE AUTOLOGOUS STEM CELL TRANSPLANTATION
title_fullStr	IMPACT OF BONE MARROW FIBROSIS IN MYELOMA PATIENTS UNDERGONE AUTOLOGOUS STEM CELL TRANSPLANTATION
title_full_unstemmed	IMPACT OF BONE MARROW FIBROSIS IN MYELOMA PATIENTS UNDERGONE AUTOLOGOUS STEM CELL TRANSPLANTATION
title_sort	impact of bone marrow fibrosis in myeloma patients undergone autologous stem cell transplantation
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/8fa8c444a7b34afba6e5cafc7670057e
work_keys_str_mv	AT senemmaral impactofbonemarrowfibrosisinmyelomapatientsundergoneautologousstemcelltransplantation AT muratalbayrak impactofbonemarrowfibrosisinmyelomapatientsundergoneautologousstemcelltransplantation AT bernaafacanozturk impactofbonemarrowfibrosisinmyelomapatientsundergoneautologousstemcelltransplantation AT unsalhan impactofbonemarrowfibrosisinmyelomapatientsundergoneautologousstemcelltransplantation AT merihreisaras impactofbonemarrowfibrosisinmyelomapatientsundergoneautologousstemcelltransplantation AT gultenkorkmaz impactofbonemarrowfibrosisinmyelomapatientsundergoneautologousstemcelltransplantation AT simtendagdas impactofbonemarrowfibrosisinmyelomapatientsundergoneautologousstemcelltransplantation AT aynuralbayrak impactofbonemarrowfibrosisinmyelomapatientsundergoneautologousstemcelltransplantation AT gulsumozet impactofbonemarrowfibrosisinmyelomapatientsundergoneautologousstemcelltransplantation
_version_	1718440673147879424

IMPACT OF BONE MARROW FIBROSIS IN MYELOMA PATIENTS UNDERGONE AUTOLOGOUS STEM CELL TRANSPLANTATION

Ejemplares similares